Search research articles
Contact Us
Filters
Showing results (1-10 of 63) with videos related to
Page
of 7
Sort By:
Drug Development Research
|
March 12, 2019
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
R Neethu, Timo Minssen
Personalized Medicine
|
May 16, 2018
Legal aspects of biobanking as key issues for personalized medicine and translational exploitation
Timo Minssen, Jens Schovsbo
Drug Discovery Today
|
January 13, 2018
Unlocking the full potential of open innovation in the life sciences through a classification system
Niclas Nilsson, Timo Minssen
Nature Biotechnology
|
July 9, 2015
Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
W Nicholson Price, Timo Minssen
Medical Law Review
|
July 2, 2020
When Does Stand-Alone Software Qualify as a Medical Device in the European Union?-The Cjeu's Decision in Snitem and What it Implies for the Next Generation of Medical Devices
Timo Minssen, Marc Mimler, Vivian Mak
European Journal of Health Law
|
August 15, 2023
Governing, Protecting, and Regulating the Future of Genome Editing: The Significance of ELSPI Perspectives
Santa Slokenberga, Timo Minssen, Ana Nordberg
European Journal of Health Law
|
August 15, 2023
Balancing Innovation, 'Ordre Public' and Morality in Human Germline Editing: A Call for More Nuanced Approaches in Patent Law
Duncan Matthews, Timo Minssen, Ana Nordberg
Journal of Medical Ethics
|
February 9, 2026
From AI SIM to AI twinning: a spectrum of digital representations of persons
Mark Fenwick, Paulius Jurcys, Timo Minssen
NPJ Digital Medicine
|
September 6, 2024
Navigating the EU AI Act: implications for regulated digital medical products
Mateo Aboy, Timo Minssen, Effy Vayena
JAMA
|
July 6, 2023
The Challenges for Regulating Medical Use of ChatGPT and Other Large Language Models
Timo Minssen, Effy Vayena, I Glenn Cohen
Page
of 7
Search research articles
Search
Showing results (1-10 of 63) with videos related to
Sort By:
Page
of 7
Drug Development Research
|
March 12, 2019
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
R Neethu, Timo Minssen
Personalized Medicine
|
May 16, 2018
Legal aspects of biobanking as key issues for personalized medicine and translational exploitation
Timo Minssen, Jens Schovsbo
Drug Discovery Today
|
January 13, 2018
Unlocking the full potential of open innovation in the life sciences through a classification system
Niclas Nilsson, Timo Minssen
Nature Biotechnology
|
July 9, 2015
Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
W Nicholson Price, Timo Minssen
Medical Law Review
|
July 2, 2020
When Does Stand-Alone Software Qualify as a Medical Device in the European Union?-The Cjeu's Decision in Snitem and What it Implies for the Next Generation of Medical Devices
Timo Minssen, Marc Mimler, Vivian Mak
European Journal of Health Law
|
August 15, 2023
Governing, Protecting, and Regulating the Future of Genome Editing: The Significance of ELSPI Perspectives
Santa Slokenberga, Timo Minssen, Ana Nordberg
European Journal of Health Law
|
August 15, 2023
Balancing Innovation, 'Ordre Public' and Morality in Human Germline Editing: A Call for More Nuanced Approaches in Patent Law
Duncan Matthews, Timo Minssen, Ana Nordberg
Journal of Medical Ethics
|
February 9, 2026
From AI SIM to AI twinning: a spectrum of digital representations of persons
Mark Fenwick, Paulius Jurcys, Timo Minssen
NPJ Digital Medicine
|
September 6, 2024
Navigating the EU AI Act: implications for regulated digital medical products
Mateo Aboy, Timo Minssen, Effy Vayena
JAMA
|
July 6, 2023
The Challenges for Regulating Medical Use of ChatGPT and Other Large Language Models
Timo Minssen, Effy Vayena, I Glenn Cohen
Page
of 7